Generic User Fees Jump To Cover Inflation Increase, Backlog Fee Elimination
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers paying facility fees will shoulder most of the burden as GDUFA revenue is increased in FY 2014 for inflation and rebalanced to account for the loss of the backlog fee.
You may also be interested in...
Generic Facility Fees Are Smaller Part Of Funding Picture Than Expected
GDUFA revenue sometimes differed significantly from estimates even as collections remained strong, which may create momentum to change their structure.
Generic Drug User Fees Lower Than Expected, Thanks To Higher Volume
Fiscal year 2013 fees for new ANDAs, prior approval supplements, backlogged applications and drug master files are 3%-50% below the agency’s initial projections.
Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections
Draft commitment letter could be first step down globalization road in which FDA relies more on foreign governments to boost manufacturing oversight.